EMERGENT BIOSOLUTIONS INC. Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax
EMERGENT BIOSOLUTIONS INC. (EBS) reported Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax of -$200.00 thousand for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-11-06.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax · last filed 2020-11-06
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax for the quarter ending 2020-09-30 was -$200.00K.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax for the quarter ending 2020-06-30 was $800.00K.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax for the quarter ending 2020-03-31 was $2.80M.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax for the quarter ending 2019-12-31 was $400.00K.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax for fiscal 2019 was $400.00K.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax for fiscal 2018 was $0.00.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax for fiscal 2017 was $0.00.
| Period end | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax 3 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax 3 month as first filed | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax 6 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax 6 month as first filed | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax 9 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax 9 month as first filed | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax 12 month |
|---|---|---|---|---|---|---|---|
| 2020-09-30 | -$200.00K 10-Q · filed 2020-11-06 | $600.00K derived: sum of 2 quarters · filed 2020-11-06 | $3.40M 10-Q · filed 2020-11-06 | $3.80M derived: sum of 4 quarters · filed 2020-11-06 | |||
| 2020-06-30 | $800.00K 10-Q · filed 2020-07-31 | $3.60M 10-Q · filed 2020-07-31 | $4.00M derived: sum of 3 quarters · filed 2020-07-31 | $4.00M derived: sum of 4 quarters · filed 2020-11-06 | |||
| 2020-03-31 | $2.80M 10-Q · filed 2020-05-01 | $3.20M derived: sum of 2 quarters · filed 2020-05-01 | $3.20M derived: sum of 3 quarters · filed 2020-11-06 | $3.20M derived: sum of 4 quarters · filed 2020-11-06 | |||
| 2019-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $400.00K derived: sum of 2 quarters · filed 2020-11-06 | $400.00K derived: sum of 3 quarters · filed 2020-11-06 | $400.00K 10-K · filed 2020-02-25 | |||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-06 | $3.00M 10-Q · filed 2019-11-07 | $0.00 derived: sum of 2 quarters · filed 2020-11-06 | $0.00 10-Q · filed 2020-11-06 | $4.20M 10-Q · filed 2019-11-07 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-07-31 | $1.20M 10-Q · filed 2019-08-02 | $0.00 10-Q · filed 2020-07-31 | $1.20M 10-Q · filed 2019-08-02 | |||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-01 | ||||||
| 2018-12-31 | $0.00 10-K · filed 2020-02-25 | ||||||
| 2017-12-31 | $0.00 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |